GliomaPhase 1/2TARLATEMNCT07243470
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
A Phase 1/2 study testing Tarlatamab and Temozolomide (TMZ) in people with Glioma and CNS Tumor, Adult, run by Centre Leon Berard at 12 sites in France.
Trial summary
This clinical trial is a 2-phase trial designed to evaluate the safety of tarlatamab in combination with a fixed dose of metronomic temozolomide in adolescents and adults with CNS tumors (stratified into two age-based cohorts), and to assess the clinical activity of this therapeutic strategy in three parallel… Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Glioma, CNS Tumor, Adult, CNS Tumor, Childhood
- What is being tested?
- Tarlatamab and Temozolomide (TMZ)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 12 sitesFrance
- Study dates
- 4 Nov 2025to Oct 2030
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- I1. Patients aged ≥ 12 years old at time of inform consent signature.
- I2. Histologically proven diagnosis of central nervous system (CNS) malignant tumor: IDH-mutant high-grade glioma, other high-grade glioma, or other high-grade CNS tumors.
- I3. Tumors expressing DLL3 based on IHC staining performed on archival tumor sample i.e. at least 1+ on IHC [patient with no tumor expression of DLL3 are not eligible].
- Note- This pre-screening by IHC should be optimally initiated during an ongoing line of treatment i.e. before documented progression. The ICF1 must be signed before to initiate this pre-screening.
- I4. Confirmed progressive or refractory disease after at least one line of standard therapy containing radiotherapy and for which no further effective standard therapy exists.
- I5. Evaluable or measurable disease as per iRANO criteria.
Show all 40Show fewer
- I6. Performance status (See Appendix 01):
- Karnofsky PS for pediatric patients ≥16 years of age ≥ 70%;
- Lansky PS for patients between 12 and 15y: ≥ 70%;
- PS ECOG for adult patients: 0 or 1.
- I7. Life expectancy ≥ 3 months.
- I8. Adequate end organ function according to laboratory values defined below :
- Hematologic criteria :
- Peripheral absolute neutrophil count (ANC) ≥1.5 G/L (without growth factor support within 7 days)
- Platelet count ≥ 100 G/L (unsupported for > 7 days)
- Hemoglobin ≥ 9.0 g/dL (unsupported for > 7 days)
- Renal and hepatic function :
- Creatinine
- Adult patient: Creatinine clearance as per CKD-EPI > 30 mL/min/1.73 m²
- Pediatric patients: Creatinine <1.5 ULN for age or an estimated glomerular filtration rate (GFR) > 60 mL/min/1.73m2 GFR based on the Schwartz equation (Mian and Schwartz 2017) or as per institutional guidelines
- Total bilirubin ≤1.5 x ULN (≤ 3.0 × ULN for patients with Gilbert's syndrome)
- Alanine aminotransferase (ALAT) ≤ 3 x ULN; aspartate aminotransferase (ASAT) ≤ 3 x ULN Coagulation function : Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) or activated partial thromboplastin time (APTT) ≤ 1.5 x ULN. Patients on chronic anticoagulation therapy who do not meet the criteria above may be eligible to enrol after discussion with the Sponsor.
- I9. Adequate cardiac function defined by Left ventricular ejection fraction (LVEF) ≥50% at baseline.
- I10. Adequate pulmonary function as per investigator judgment and no clinically significant pleural effusion. Pleural effusion managed with indwelling pleural catheter (e.g, PleurX) are allowed.
- I11. Availability of a representative formalin-fixed paraffin-embedded (FFPE) sample of tumor tissue (resection or biopsy, archival) with an associated pathology report must be available. This tumor sample must meet the following quality/quantity control criteria: ≥30 % of tumor cells.
- I12. Patients must have discontinued all previous anti-cancer treatments (approved or investigational) for CNS treatment with respect of wash-out period at time of C1D1 as shown below:
- Cytotoxic and myelosuppressive chemotherapy : ≥21 days (or ≥42 days if prior nitrosourea)
- Metronomic chemotherapy regimen : ≥21 days or ≥5 half-lives of the treatment with the longest half-life (whichever is shorter)
- Targeted agent : ≥21 days or ≥5 half-lives (whichever is shorter)
- Cellular therapy : ≥42 days for any type of cellular therapy (e.g. modified T cells, NK cells, dendritic cells) agent
- Antibody therapy : ≥21 days after the last infusion except for bevacizumab for which a wash out period of 3 months is requested
- Radiotherapy :
- ≥14 days since small port radiation therapy (i.e. local palliative)
- ≥84 days since large-field radiation therapy (i.e. TBI, craniospinal, whole abdominal, total lung, ≥50% or greater pelvic radiation, ≥50% marrow space)
- ≥42 days for other substantial bone marrow radiation
- Surgery : Major surgery ≥ 21 days. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48-hour interval must be maintained before C1D1
- I13. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior C1D1 and must agree to use highly effective contraceptive measures starting with the Screening Visit through 6 months after the last dose of study drugs and to not breastfeed during this period. Highly effective contraception is defined in Appendix 02.
- I14. Sexually active male must agree to use adequate and appropriate contraception while on study drugs and for 6 months after stopping the study drugs.
- I15. Ability to understand and sign informed consent and willingness to comply with the study procedures before study entry and written informed consent from parents/legal representative, patient, and age-appropriate assent before any study-specific screening procedures are conducted according to local, regional or national guidelines.
- I16. Covered by a medical insurance.
Who cannot join
- E1. Diagnosis of non-CNS tumor.
- E2. Diagnosis of diffuse intrinsic pontine glioma.
- E3. Current treatment with bevacizumab.
- E4. Prior treatment with a DLL3-directed therapy. Note: Prior treatment with TMZ is not an exclusion criteria.
- E5. Neurologically unstable or require increasing doses of corticosteroids during the 7 days before C1D1 or local CNS-directed therapy to control their CNS disease. Note: Patients on low doses of corticosteroids (< 0.25mg/kg/d of prednisolone or equivalent) during the 7 days prior to receiving study drugs are eligible.
- E6. Evidence of Grade > 1 recent CNS hemorrhage on the baseline MRI scan.
Show all 32Show fewer
- E7. Bulky tumor on imaging defined as:
- Tumor with any evidence of uncial herniation or severe midline shift ii. Tumor with diameter of > 6 cm in one dimension on contrast-enhanced MRI iii. Tumor that in the opinion of the investigator shows significant mass effect.
- E8. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome)
- E9. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to C1D1.
- E10. Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 6 months of C1D1).
- E11. Other malignancy unless this malignancy is not expected to interfere with the evaluation of study endpoints (basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, localized prostate cancer), or with no evidence of disease for ≥ 2 years.
- E12.History of hypophysitis or pituitary dysfunction.
- E13.History of severe allergic or other hypersensitivity reactions to
- chimeric or humanized antibodies or fusion proteins,
- biopharmaceuticals produced in Chinese hamster ovary cells,
- or any component of the tarlatamab formulation.
- E14.Known hypersensitivity to any study drug or component of the formulation or to dacarbazine or TMZ.
- E15.Acute and ongoing toxicities from previous therapy that have not resolved to Grade ≤1, except for alopecia, neuropathy, ototoxicity and lab values presented in inclusion criteria.
- E16.Arterial thrombosis or a history of pulmonary embolism who need anticoagulants.
- E17.Evidence of interstitial lung disease or active, non-infectious pneumonitis.
- E18.Recurrent pneumonitis (grade 2 or higher) or grade≥3 immune-mediated adverse events or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immuno-oncology agents.
- E19. Live vaccines injection within 4 weeks before C1D1. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever and BCG. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed.
- E20. Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years of the start of study treatment (i.e., with use of disease-modifying agents or immunosuppressive drugs).
- E21. Documentation of:
- Active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) unless their HBV is stably controlled on nucleoside analogs (eg entecavir or tenofovir) which will be continued for the duration of the study.
- Note: Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior to C1D1.
- Active hepatitis C. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA, or
- HIV infection
- E22. Prior organ or bone marrow transplant
- E23. History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
- E24. Pregnant or breastfeeding women.
Trial locations and contacts
12 sites in 1 country. Contact the study team or a site near you to ask about taking part.
12 sites in 1 country
France12 sites, 12 recruiting
- Recruiting
Institut de Cancérologie de l'Ouest
Angers, 49055
Pierre KUBICEK, MD, +33241352700, pierre.kubicek@ico.unicancer.fr
Pierre KUBICEK
- Recruiting
Centre Hospitalier Universitaire d'Angers
Angers, 49933
Claire BRISSET, MD, +33241353863, claire.brisset@chu-angers.fr
Claire BRISSET
- Not yet recruiting
CHU de Bordeaux
Bordeaux, 33000
Céline ICHER, MD, +33557820448, celine.icher@chu-bordeaux.fr
Céline ICHER
- Recruiting
Hôpital Saint-André
Bordeaux, 33075
Mathieu LARROQUETTE, +33556795808, mathieu.larroquette@chu-bordeaux.fr
Mathieu LARROQUETTE
- Recruiting
Hôpital Neurologique Pierre Wertheimer
Bron, 69677
François DUCRAY, MD, +33472681321, francois.ducray@chu-lyon.fr
François DUCRAY
- Not yet recruiting
Centre Oscar Lambret
Lille, 59000
François SEVRIN, MD, +33320295959, f-sevrin@o-lambret.fr
François SEVRIN
- Recruiting
Centre Léon Bérard
Lyon, 69373
Pierre LEBLOND, MD, PhD, +33469166550, pierre.leblond@ihope.fr
Aurélien MAUREILLE, MD, +33469166645, aurelien.maureille@lyon.unicancer.fr
- Recruiting
Hôpital de la Timone - service adulte
Marseille, 13005
Emeline TABOURET, MD, +33491384644, emeline.tabouret@ap-hm.fr
Emeline TABOURET
- Recruiting
Hôpital de la Timone - service pédiatrie
Marseille
Nicolas ANDRE, MD, +33491386821, nicolas.andre@ap-hm.fr
Nicolas ANDRE
- Not yet recruiting
Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix
Paris, 75013
Medhi TOUAT, MD, +33142160385, mehdi.touat@aphp.fr
Mehdi TOUAT
- Recruiting
IUCT - Claudius Regaud
Toulouse, 31100
Delphine LARRIEU-CIRON, MD, +33531155674, larrieuciron.delphine@iuct-oncopole.fr
Delphine LARRIEU-CIRON
- Not yet recruiting
Institut Gustave Roussy
Villejuif, 94085
Jacques GRILL, MD, +33142116209, jacques.grill@gustaveroussy.fr
Jacques GRILL
About this study
Official title: A Multicenter, Open-label Phase I/II Trial Aiming to Assess the Safety and Clinical Activity of Tarlatamab in Combination With Metronomic Temozolomide in Adolescents and Adults' Patients With High Grade Brain Tumors
This clinical trial is a 2-phase trial designed to evaluate the safety of tarlatamab in combination with a fixed dose of metronomic temozolomide in adolescents and adults with CNS tumors (stratified into two age-based cohorts), and to assess the clinical activity of this therapeutic strategy in three parallel, histology-defined cohorts (IDH-mutant glioma, other gliomas, and other CNS tumors). A pre-screening to detect DLL3 expression by IHC on archival tumor sample must be performed before the therapeutic part. Only patients with DLL3 positive tumor on IHC can be enrolled in the therapeutic part. This pre-screening must be optimally performed during the ongoing treatment line i.e. before documented progression to not delay treatment starts at time of progression. Tumor samples (surgery or biopsy specimen) will be sent to a central lab for IHC testing.
- Conditions
- Glioma, CNS Tumor, Adult, CNS Tumor, Childhood
- Being tested
- Tarlatamab, Temozolomide (TMZ)
- Keywords
- temozolomide, tarlatamab, phase 1/2, RP2D, glioma
- Medical subject headings
- Glioma, Central Nervous System Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TarlatamabDrug
At the starting dose (DL1): All patients will receive a step dose (1 mg) on C1D1 administered as a 60-minute intravenous (IV) infusion then 10mg at C1D8 and C1D15 of tarlatamab single agent (no temozolomide administered during cycle 1) then tarlatamab at 10mg every D1 \& D15 of each 4-week cycle thereafter in combination with temozolomide from C2D1.
At DL-1: a cycle period will be 6 weeks with tarlatamab administration every 3 weeks after Cycle 1.
Temozolomide (TMZ)Drug
Also called Temodal
At DL1 : Metronomic temozolomide will not be administered during the first cycle. It will be administered from the first day of the second cycle, at a dose of 50 mg/m²/day, continuously.
At DL-1 : Metronomic temozolomide will not be administered during the first cycle. It will be administered from the first day of the second cycle, at a dose of 50 mg/m²/day, continuously.
| Study group | Role | What they receive |
|---|---|---|
| Patients with IDH-mutant glioma | Experimental | Patients must have histologically confirmed diagnosis of central nervous system (CNS) malignant tumor: IDH-mutant high-grade glioma, other high-grade glioma or other high-grade CNS tumors. Receives: Drug: Tarlatamab; Drug: Temozolomide (TMZ) |
| Patients with other glioma | Experimental | Patients must have histologically confirmed diagnosis of central nervous system (CNS) malignant tumor: IDH-mutant high-grade glioma, other high-grade glioma or other high-grade CNS tumors. Receives: Drug: Tarlatamab; Drug: Temozolomide (TMZ) |
| Patients with other CNS tumors | Experimental | Patients must have histologically confirmed diagnosis of central nervous system (CNS) malignant tumor: IDH-mutant high-grade glioma, other high-grade glioma or other high-grade CNS tumors. Receives: Drug: Tarlatamab; Drug: Temozolomide (TMZ) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase I : Dose limiting toxicities (DLT) assessed as related at least to tarlatamab, occurring during the first 2 cycles of treatment
Dose limiting toxicities (DLT) defined as the following adverse event (AE) graded according to NCI CTCAE V5.0 or specific grading system for ICANS and CRS, assessed as related at least to tarlatamab, occurring during the first 2 cycles of treatment (i.e. DLT period is 8 weeks for DL1 or 12 weeks if DL-1 is investigated) : - Any Grade 4 non-laboratory toxicity (including CRS).
- Any Grade 3 non-laboratory toxicity (including CRS) lasting >7 days despite optimal supportive care and with the following exceptions: Grade 3 fatigue, Grade ≥ 3 Diarrhea/Vomiting/Nausea adequately managed with supportive care measures within 14 days.
- Grade ≥ 3 ICANS.
- Any Grade 3 or Grade 4 laboratory value if medical intervention is required or the abnormality persists for >1 week.
- Febrile neutropenia Grade ≥ 3
- Grade 4 anemia
- Any Grade 5 toxicity (i.e., toxic death)
- Any other significant toxicity deemed by the investigator and/or member of the steering meeting to be dose limiting.
Measured: From Cycle 1 Day 1 to week 8
Phase II : To assess the clinical activity of the proposed therapeutic strategy in 3 parallel and independent cohorts of CNS tumors (IDH-mutant glioma, other glioma and other CNS tumors).
Objective response rate at 12 weeks (ORR-12W) according to immunotherapy Response Assessment for Neuro-Oncology (iRANO) criteria
Measured: 12 weeks from the date of first study drug administration (Cycle 1 Day 1)
Secondary outcomes (6)
Evaluation of the Duration of Response (DoR)
Measured: From the time of first documented response (Complete Response or Partial Response as per iRANO) until the first documented disease progression or death due to underlying cancer, or censored at the date of the last available tumor assessment
Evaluation of the time to objective response (ToR)
Time to objective Response is defined as time to first documented objective response (Complete Response or Partial Response as per iRANO) following Cycle 1 Day 1
Measured: From Cycle 1 Day 1 to first documented objective response
Evaluation of Disease Control Rate (DCR)
Disease Control Rate (DCR) will be calculated as the percentage of patients who achieve complete response, partial response, or at least six months of stable disease.
Measured: From enrollment to the end of treatment at 12 months
Evaluation of Progression-Free Survival (PFS)
Progression-Free Survival will be measured from C1D1 to the date of the first disease progression or death and will be estimated using the Kaplan-Meier method.
Measured: From Cycle 1 Day 1 to the date of the first disease progression or death
Evaluation of Overall Survival (OS)
Overall survival will be estimated using the Kaplan-Meier method.
Measured: From Cycle 1 Day 1 to the date of death from any cause
To collect nature, incidence and severity of Adverse Events graded using Common Terminology Criteria for Adverse Events (CTCAE) V5.0 or specific grading system for ICANS and CRS [safety and tolerability]
To characterize the safety and tolerability profile of the proposed therapeutic strategy
Measured: From enrollment to the end of treatment at 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2025
- Study start4 Nov 2025
- Primary completionOct 2029 (estimated)
- Study completionOct 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (45)Papers the sponsor has linked to this study.
- Other trials for GliomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- The study consists of 2 parts: A Phase I (safety run-in) part to confirm the safety of tarlatamab single agent followed by combination with a fixed dose of metronomic temozolomide (TMZ). Patients start at DL1 with a test dose of tarlatamab 1 mg (C1D1), followed by 10 mg on D8 and D15 of cycle 1 without TMZ. From cycle 2 onward, they receive 10 mg of tarlatamab on D1 and D15 of each 4-week cycle in combination with TMZ. Adult safety run in cohort will be opened first, then adolescent safety run in cohort will be evaluated only once the adult safety run in is cleared. A one-week delay period between each pediatric enrolment will be required during pediatric safety run in. A Phase II part to assess the clinical activity of the proposed strategy in 3 independent and parallel cohorts: IDH-mutant high-grade glioma, other high-grade glioma, and other high-grade CNS tumors. Enrolment in phase II will be possible only after validation of safety run in in adults then in paediatric patients.
- Masking
- None (open label)
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Leon Berard
- Sponsor type
- University, hospital or other
- Collaborators
- Amgen, National Cancer Institute, France
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07243470
- Sponsor's protocol ID
- ET23-040
- Other IDs
- 2023-510568-11-00, 2023
- Acronym
- TARLATEM
- Status last verified
- May 2026
- First submitted
- 30 Sep 2025
- Last updated
- 14 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Baruchel S, Diezi M, Hargrave D, Stempak D, Gammon J, Moghrabi A, Coppes MJ, Fernandez CV, Bouffet E. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer. 2006 Sep;42(14):2335-42. doi: 10.1016/j.ejca.2006.03.023. Epub 2006 Aug 8.
PubMed 16899365Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997 Jan;23(1):35-61. doi: 10.1016/s0305-7372(97)90019-0. No abstract available.
PubMed 9189180Farago A.et al. dynamics of DLL3 and ASCL1 expression in SCLC over disease course. J Thorac Oncol. 2018; 13: S970-S971
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov;16(15):e534-e542. doi: 10.1016/S1470-2045(15)00088-1.
PubMed 26545842Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. doi: 10.1002/cncr.22961.
PubMed 17705175Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol. 2013 Feb;15(2):242-50. doi: 10.1093/neuonc/nos295. Epub 2012 Dec 14.
PubMed 23243055Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, Dong SM, Nam DH. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol. 2010 Mar;12(3):289-96. doi: 10.1093/neuonc/nop030. Epub 2010 Jan 11.
PubMed 20167817Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Canete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. J Clin Oncol. 2018 Apr 1;36(10):951-958. doi: 10.1200/JCO.2017.76.0611. Epub 2018 Feb 7.
PubMed 29412784Broniscer A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, Bowers DC, Iacono LC, Merchant TE, Stewart CF, Houghton PJ, Kun LE, Ledet D, Gajjar A. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol. 2006 Feb;76(3):313-9. doi: 10.1007/s11060-005-7409-5.
PubMed 16200343Jakacki RI, Cohen KJ, Buxton A, Krailo MD, Burger PC, Rosenblum MK, Brat DJ, Hamilton RL, Eckel SP, Zhou T, Lavey RS, Pollack IF. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. Neuro Oncol. 2016 Oct;18(10):1442-50. doi: 10.1093/neuonc/now038. Epub 2016 Mar 22.
PubMed 27006176Patel M, McCully C, Godwin K, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol. 2003 Feb;61(3):203-7. doi: 10.1023/a:1022592913323.
PubMed 12675312Panetta JC, Kirstein MN, Gajjar A, Nair G, Fouladi M, Heideman RL, Wilkinson M, Stewart CF. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol. 2003 Dec;52(6):435-41. doi: 10.1007/s00280-003-0670-4. Epub 2003 Sep 16.
PubMed 13680158Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, Stupp R. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004 Jun 1;10(11):3728-36. doi: 10.1158/1078-0432.CCR-03-0807.
PubMed 15173079Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother. 2009 Oct;58(10):1627-34. doi: 10.1007/s00262-009-0671-1. Epub 2009 Feb 17.
PubMed 19221744Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, Son MJ, Song HS, Shin HJ, Lee DS, Eoh W, Nam DH. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep. 2006 Jul;16(1):33-9.
PubMed 16786120